Novartis Gains Access to Celyad’s allogenic CAR-T cell patents – Labiotech.eu (blog)
|
Novartis Gains Access to Celyad’s allogenic CAR–T cell patents
Labiotech.eu (blog) Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR–T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing “off-the-shelf” therapies, based on engineering donor-derived allogeneic T cells. Celyad (CYAD), Novartis (NVS) Enter Non-Exclusive License for Allogeneic TCR-Deficient CAR–T CellsStreetInsider.com Novartis takes the long view on CAR–T, grabbing licenses on new tech for next-gen therapiesEndpoints News |
Endpoints News |
Novartis Gains Access to Celyad’s allogenic CAR–T cell patents
Labiotech.eu (blog) Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR–T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing “off-the-shelf” therapies, based on engineering donor-derived allogeneic T cells. Celyad (CYAD), Novartis (NVS) Enter Non-Exclusive License for Allogeneic TCR-Deficient CAR–T CellsStreetInsider.com Novartis takes the long view on CAR–T, grabbing licenses on new tech for next-gen therapiesEndpoints News |
Genetic Engineering & Biotechnology News |
CRISPR Eliminates HIV in Live Animals
Genetic Engineering & Biotechnology News This is the first study to demonstrate that HIV-1 replication can be completely shut down and the virus eliminated from infected cells in animals with a powerful gene-editing technology known as CRISPR/Cas9. The new work builds on a previous … Temple uses gene-editing to eliminate HIV infection in micePhilly.com Temple researchers first to remove HIV-1 infection from live animalsPhillyVoice.com Gene-editing removes HIV-1 infection from live animals in studyUPI.com Highlander Newspaper –University Herald all 10 news articles » |
pharmaphorum |
AstraZeneca Wins FDA Nod for Bladder Cancer Immunotherapy Imfinzi
Genetic Engineering & Biotechnology News AstraZeneca has won FDA approval for its advanced bladder cancer candidate Imfinzi™ (durvalumab), which the pharma giant declared will be the cornerstone of an “extensive” immuno-oncology program across multiple cancer types and stages of disease. FDA Approves Imfinzi Immunotherapy for Bladder CancerP&T Community AZ’s Imfinzi joins the immunotherapy contestpharmaphorum |
Street Register |
US Stem Cell Inc (OTCMKTS:USRM) Extends Rise After Private Equity Firm Commits to Share Purchase
Street Register If you’ve never heard of US Stem Cell Inc, it’s a biotech company that is primarily focused on the research and development, discovery, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Since US Stem … US Stem Cell Inc (OTCMKTS:USRM) Receives Institutional Fund InjectionStockNewsUnion Stock in Focus: U.S. Stem Cell, Inc. (OTCPK:USRM)Lenox Ledger |
Genetic Literacy Project |
Meet CRISPR: Our Genetic Superweapon
Geek CRISPR (pronounced “crisper”) is, essentially, a genetic scalpel that allows us to slice parts of the DNA in living cells. That sounds scary — and it definitely is. If used poorly, we could well be talking about a very different kind of superweapon … CRISPR primer: Explaining the powerful gene-editing toolGenetic Literacy Project Italy: CRISPR-Cas 9 is the new genetic frontierFreshPlaza |
|
BRIEF-Abeona Therapeutics provides update on EB-101 gene therapy
Reuters Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news … |
|
BRIEF-Abeona Therapeutics provides update on EB-101 gene therapy
Reuters Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news … |